---
title: "AIM ImmunoTech Inc. (AIM.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/AIM.US/overview.md"
symbol: "AIM.US"
name: "AIM ImmunoTech Inc."
parent: "https://longbridge.com/zh-CN/quote/AIM.US.md"
datetime: "2026-04-15T19:06:51.994Z"
locales:
  - [en](https://longbridge.com/en/quote/AIM.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AIM.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AIM.US/overview.md)
---

# AIM ImmunoTech Inc. (AIM.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | 生物技术 |
| 交易所 | US Market |
| 地址 | 2117 SW Highway 484, Ocala, Florida, United States |
| 官网 | [aimimmuno.com](https://aimimmuno.com) |

## 公司简介

AIM ImmunoTech Inc.是一家免疫药物公司，专注于在美国研发治疗多种癌症、病毒性疾病和免疫缺陷疾病的疗法。其旗舰产品为 Ampligen（rintatolimod），这是一种用于治疗慢性疲劳综合症的大分子双链核糖核酸药物；以及 Alferon N Injection（干扰素α），这是一种纯化的天然来源的糖基化多物种α干扰素产品，用于治疗生殖器疣。该公司还在开发 Ampligen，以期用于治疗胰腺癌、肾细胞癌、恶性黑色素瘤、非小细胞肺癌、卵巢癌、乳腺癌、结直肠癌和前列腺癌，以及用于治疗肌痛性脑脊髓炎、乙型肝炎、HIV、COVID-19 和后 COVID 症状。该公司曾被称为 Hemispherx Biopharma, Inc

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Thomas K. Equels | Executive Vice Chairman, CEO & President |
| William M. Mitchell | Independent Chairman of the Board & Member of Scientific Advisory Board |
| Robert Dickey | Chief Financial Officer |
| Peter W. Rodino | COO, Executive Director of Governmental Relations, General Counsel & Secretary |
| Ann Marie E. Coverly | Director of Administration & Human Resources and Deputy Investor Relations Coordinator |
| Christopher Nicodemus | Member of Scientific Advisory Board & Consulting Science Officer |
| W. Neal Burnette | Chairman of Scientific Advisory Board |
| Nancy K. Bryan | Independent Director |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| DRW Holdings, LLC | 0.85% | 2025-12-31 |
| Thomas K. Equels | 0.78% | 2026-03-12 |
| Ted Douglas Kellner | 0.46% | 2025-10-24 |
| Armistice Capital LLC | 0.41% | 2024-12-31 |
| David I. Chemerow | 0.35% | 2026-03-12 |
| The Vanguard Group, Inc. | 0.22% | 2025-12-31 |
| Geode Capital Management, LLC | 0.21% | 2025-12-31 |
| Todd A. Deutsch | 0.21% | 2024-12-19 |
| William M. Mitchell | 0.06% | 2025-10-24 |
| Peter W. Rodino | 0.05% | 2025-10-24 |

## 业务构成

| 业务线 | 营收 | 占比 |
|---------|---------|-------|
| 基于自然免疫系统的新药治疗的临床开发 | 88000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "AIM ImmunoTech Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "基于自然免疫系统的新药治疗的临床开发",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地区分布

| 地区 | 营收 | 占比 |
|--------|---------|-------|
| 美国 | 88000 | 100% |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**